Clinical Trials

Papers
(The H4-Index of Clinical Trials is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Rethinking intercurrent events in defining estimands for tuberculosis trials42
Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges33
A review of current practice in the design and analysis of extremely small stepped-wedge cluster randomized trials30
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials23
A critique on “A randomized evaluation of on-site monitoring nested in a multinational randomized trial”23
Industry payments and brand-name tyrosine kinase inhibitor use amid generic entry23
Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial22
Random effect misspecification in stepped wedge designs21
Effects of patient-reported outcome assessment order21
What do we do with our under-enrolled single-center COVID-19 clinical trials?21
A Bayesian adaptive design approach for stepped-wedge cluster randomized trials19
Modeling impact of inflation reduction act price negotiations on new drug pipeline considering differential contributions of large and small biopharmaceutical companies19
Clinical trial site identification practices and the use of electronic health records in feasibility evaluations: An interview study in the Nordic countries18
Characterization of studies considered and required under Medicare’s coverage with evidence development program16
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials15
Partner engagement for planning and development of non-pharmacological care pathways in the AIM-Back trial15
Importance of patient engagement in the conduct of pragmatic multicenter randomized controlled trials: The ADAPTABLE experience15
Influential methods reports for group-randomized trials and related designs15
0.047631025314331